- Q3 2026 revenue increased 83% year-over-year to
$39.1 million - Net loss of
$3.5 million , a 10% year-over-year improvement - Increasing 2026 revenue outlook to
$145 million U.S . revenues more than doubled quarter over quarter (QoQ)
Revenue for the third quarter of 2026 was
Q3 2026 Financial Highlights
- Record revenue of
$39.1 million , up 15% sequentially and 83% year-over-year (YoY) - Gross profit of
$10.5 million , up$7.2 million and 217% YoY - GAAP gross margin of 27%, improving from 15% in Q3 2025
- Net loss attributable to common stockholders of
$3.5 million , a$0.4 million improvement YoY - Non-GAAP Adjusted EBITDA of
($1.0) million , a decrease from$0.2 million in Q3 2025 U.S . revenues increased by 2.3X quarter-over-quarter (QoQ) to$12.2 million
"Our third quarter results demonstrate the strength of our company’s technology leadership and our ability to convert growing customer demand into meaningful financial performance," said
Reconciliations of GAAP net loss to non-GAAP adjusted net loss and non-GAAP adjusted EBITDA are provided in the financial schedules that are part of this press release. An explanation of these non-GAAP financial measures is also included below under the heading "Non-GAAP Financial Measures.”
Quarterly Financial Comparison
$ in millions
Metric | Q3 2026 | Q3 2025 | Delta | Improvement |
Revenue | 39.1 | 21.4 | 17.7 | 83% |
Gross Profit | 10.5 | 3.3 | 7.2 | 217% |
% Margin | 27% | 15% |
|
|
GAAP Net Loss | (3.5) | (3.9) | 0.4 | 10% |
% Margin | (9%) | (18%) |
|
|
Non-GAAP Adjusted EBITDA | (1.0) | 0.2 | (1.2) | NM |
% Margin | (3%) | 1% |
|
|
Business Highlights
- Secured a
$75 million U.S. Department of War competitive contract to produce cells in theU.S .,$22.3 million of which is obligated, by supporting the conversion of an existing battery production line with planned output of up to 12 million NDAA-compliant cells annually in 2028. - Introduced SiCore® 500, a second-generation silicon anode cell delivering 500 Wh/kg on conventional lithium-ion manufacturing equipment, enabling a scalable path to large-scale commercial production to support aviation customers.
- Expanded our relationship with Quantum Systems, a leading German developer of autonomous unmanned systems, with increased deployment of
Amprius cells across its Vector and Twister ISR platforms. - Began supplying SiCore cells to a U.S. aerospace company producing a solar-powered stratospheric platform. Our cell supports extended-duration missions where energy density and weight are critical performance requirements.
- Secured a design win with a global leader in maritime and defense technology, for an autonomous deep-sea underwater vehicle platform, extending the application of
Amprius' SiCore technology into subsea defense and maritime markets.
Updated 2026 Financial Outlook
- Revenue is expected to be
$145 million , raised from at least$140 million - Gross margin is expected to be at least 28%
- Net loss is expected to be less than
$10 million , including the Q2$1.9 million non-cash fair value charge impact of the Warrant Exchange - Net loss per share is expected to be under
$0.07 - Adjusted EBITDA is expected to be at least
$2.5 million - Capital expenditure is expected to be under
$10 million
The Company's 2026 outlook assumes depreciation and amortization of
Amprius’ CFO
Conference Call and Webcast Notification
A conference call with
Shareholders and other interested parties may call 866-424-3442 (domestic) or +1 201-689-8548 (international) and reference conference ID “13763371” to participate in the conference call. In addition, the conference call and an accompanying slide presentation will be available live as a listen-only webcast here and hosted at the Investor Relations section of Amprius’ website, ir.amprius.com.
Following the live event, an archived version of the webcast will be available on Amprius’ website for convenient on-demand replay. A copy of this press release is posted in the Investor Relations section on Amprius’ website.
About
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, each as amended, including Amprius’ expectations, hopes, beliefs, intentions or strategies regarding the future. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “will” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the ability of
Non-GAAP Financial Measures
To supplement our financial results presented on a basis in conformity with generally accepted accounting principles in
Management believes that these non-GAAP financial measures reflect our ongoing business in a manner that allows for meaningful comparisons and analysis of trends in its business, as it excludes expenses and gains not reflective of ongoing operating results or that may be infrequent and/or unusual in nature. We exclude the non-cash impact of the increase in fair value related to the warrant exchange, as the exchange of warrants for common shares is not related to our ongoing operations. We exclude the operating costs for our former facility in
Management also believes that these non-GAAP financial measures provide useful information to investors in understanding and evaluating our operating results and future prospects in the same manner as management and in comparing financial results across accounting periods and to those of peer companies. These non-GAAP measures may not be comparable to similarly titled measures presented by other companies. In this press release, we provided reconciliations of non-GAAP adjusted net loss and non-GAAP Adjusted EBITDA to GAAP net loss, the most directly comparable GAAP financial measure.
CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
(Unaudited, in thousands, except share and par value data) | |||||||
|
|
|
| ||||
ASSETS |
|
|
| ||||
Current assets: |
|
|
| ||||
Cash and cash equivalents | $ | 60,685 |
|
| $ | 90,465 |
|
Accounts receivable, net |
| 45,859 |
|
|
| 23,737 |
|
Inventories |
| 15,890 |
|
|
| 6,735 |
|
Prepaid expenses and other current assets |
| 18,901 |
|
|
| 5,500 |
|
Total current assets |
| 141,335 |
|
|
| 126,437 |
|
Non-current assets: |
|
|
| ||||
Property, plant and equipment, net |
| 16,242 |
|
|
| 9,680 |
|
Operating lease right-of-use assets, net |
| 6,515 |
|
|
| 19,518 |
|
Other assets |
| 63 |
|
|
| 1,256 |
|
Total assets | $ | 164,155 |
|
| $ | 156,891 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
| ||||
Current liabilities: |
|
|
| ||||
Accounts payable | $ | 13,362 |
|
| $ | 6,700 |
|
Accrued and other current liabilities |
| 16,189 |
|
|
| 3,666 |
|
Deferred grant |
| 2,738 |
|
|
| 2,738 |
|
Deferred revenue |
| 92 |
|
|
| 100 |
|
Operating lease liabilities |
| 1,175 |
|
|
| 4,665 |
|
Total current liabilities |
| 33,556 |
|
|
| 17,869 |
|
Non-current liabilities: |
|
|
| ||||
Operating lease liabilities |
| 5,904 |
|
|
| 35,207 |
|
Total liabilities |
| 39,460 |
|
|
| 53,076 |
|
Commitments and contingencies |
|
|
| ||||
Stockholders’ equity: |
|
|
| ||||
Preferred stock; no shares issued and outstanding |
| — |
|
|
| — |
|
Common stock; and 134,536,592 shares issued and outstanding at |
| 14 |
|
|
| 13 |
|
Additional paid-in capital |
| 354,703 |
|
|
| 322,156 |
|
Accumulated other comprehensive income |
| 35 |
|
|
| 4 |
|
Accumulated deficit |
| (230,057 | ) |
|
| (218,358 | ) |
Total stockholders’ equity |
| 124,695 |
|
|
| 103,815 |
|
Total liabilities and stockholders’ equity | $ | 164,155 |
|
| $ | 156,891 |
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
(Unaudited, in thousands, except share and per share data) | ||||||||||||||||
|
| Three months ended |
| Nine months ended | ||||||||||||
|
|
| 2026 |
|
|
| 2025 |
|
|
| 2026 |
|
|
| 2025 |
|
Revenue |
| $ | 39,145 |
|
| $ | 21,426 |
|
| $ | 101,713 |
|
| $ | 47,777 |
|
Cost of revenue |
|
| 28,630 |
|
|
| 18,108 |
|
|
| 76,178 |
|
|
| 45,480 |
|
Gross profit (loss) |
|
| 10,515 |
|
|
| 3,318 |
|
|
| 25,535 |
|
|
| 2,297 |
|
Gross margin |
|
| 27 | % |
|
| 15 | % |
|
| 25 | % |
|
| 5 | % |
Operating expenses: |
|
|
|
|
|
|
|
| ||||||||
Research and development |
|
| 6,407 |
|
|
| 2,509 |
|
|
| 14,305 |
|
|
| 6,674 |
|
Selling, general and administrative |
|
| 8,834 |
|
|
| 5,501 |
|
|
| 26,941 |
|
|
| 16,799 |
|
Total operating expenses |
|
| 15,241 |
|
|
| 8,010 |
|
|
| 41,246 |
|
|
| 23,473 |
|
Loss from operations |
|
| (4,726 | ) |
|
| (4,692 | ) |
|
| (15,711 | ) |
|
| (21,176 | ) |
Other income, net |
|
| 1,227 |
|
|
| 800 |
|
|
| 4,012 |
|
|
| 1,543 |
|
Net loss |
|
| (3,499 | ) |
|
| (3,892 | ) |
|
| (11,699 | ) |
|
| (19,633 | ) |
Increase in net loss due to warrant modification |
|
| — |
|
|
| — |
|
|
| (1,921 | ) |
|
| — |
|
Net loss attributable to common stockholders |
| $ | (3,499 | ) |
| $ | (3,892 | ) |
| $ | (13,620 | ) |
| $ | (19,633 | ) |
Weighted-average common shares outstanding: |
|
|
|
|
|
|
|
| ||||||||
Basic and diluted |
|
| 146,332,565 |
|
|
| 126,630,085 |
|
|
| 142,283,973 |
|
|
| 122,137,964 |
|
Net loss per share of common stock: |
|
|
|
|
|
|
|
| ||||||||
Basic and diluted |
| $ | (0.02 | ) |
| $ | (0.03 | ) |
| $ | (0.10 | ) |
| $ | (0.16 | ) |
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||
(Unaudited, in thousands) | |||||||
| Nine months ended | ||||||
|
| 2026 |
|
|
| 2025 |
|
Cash flows from operating activities: |
|
|
| ||||
Net loss | $ | (11,699 | ) |
| $ | (19,633 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
| ||||
Stock-based compensation |
| 7,071 |
|
|
| 5,491 |
|
Depreciation and amortization |
| 2,266 |
|
|
| 3,142 |
|
Loss on termination of lease |
| 166 |
|
|
| — |
|
Write-down of property, plant and equipment |
| 77 |
|
|
| — |
|
Non-cash operating lease expense |
| 1,239 |
|
|
| 3,857 |
|
Gain on disposal of property, plant and equipment |
| (355 | ) |
|
| — |
|
Other non-cash items |
| (22 | ) |
|
| 444 |
|
Changes in operating assets and liabilities: |
|
|
| ||||
Accounts receivable, net |
| (22,035 | ) |
|
| (16,781 | ) |
Inventories |
| (9,147 | ) |
|
| 1,895 |
|
Prepaid expenses and other current assets |
| (12,342 | ) |
|
| (2,495 | ) |
Other assets |
| (22 | ) |
|
| 26 |
|
Accounts payable |
| 6,096 |
|
|
| 467 |
|
Accrued and other current liabilities |
| 11,946 |
|
|
| (538 | ) |
Deferred revenue |
| (8 | ) |
|
| (933 | ) |
Operating lease liabilities |
| (21,195 | ) |
|
| (2,579 | ) |
Net cash used in operating activities |
| (47,964 | ) |
|
| (27,637 | ) |
Cash flows from investing activities: |
|
|
| ||||
Purchase of property, plant and equipment |
| (7,979 | ) |
|
| (2,043 | ) |
Proceeds from the disposal of property, plant and equipment |
| 355 |
|
|
| — |
|
Net cash used in investing activities |
| (7,624 | ) |
|
| (2,043 | ) |
Cash flows from financing activities: |
|
|
| ||||
Proceeds from issuance of common stock in connection with the At Market Issuance Sales Agreement, net |
| — |
|
|
| 44,053 |
|
Proceeds from exercise of warrants |
| 14,182 |
|
|
| — |
|
Proceeds from exercise of stock options |
| 11,295 |
|
|
| 3,899 |
|
Net cash provided by financing activities |
| 25,477 |
|
|
| 47,952 |
|
Net (decrease) increase in cash, cash equivalents and restricted cash equivalents |
| (30,111 | ) |
|
| 18,272 |
|
Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents |
| 31 |
|
|
| (3 | ) |
Cash, cash equivalents and restricted cash equivalents, beginning of period |
| 91,921 |
|
|
| 56,411 |
|
Cash, cash equivalents and restricted cash equivalents, end of period | $ | 61,841 |
|
| $ | 74,680 |
|
|
|
|
| ||||
Reconciliation of cash, cash equivalents and restricted cash equivalents shown on the condensed consolidated balance sheets: |
|
|
| ||||
Cash and cash equivalents | $ | 60,685 |
|
| $ | 73,224 |
|
Restricted cash equivalents included in prepaid expenses and other current assets |
| 1,100 |
|
|
| 200 |
|
Restricted cash equivalents included in other assets |
| 56 |
|
|
| 1,256 |
|
Total cash, cash equivalents and restricted cash equivalents | $ | 61,841 |
|
| $ | 74,680 |
|
GAAP TO NON-GAAP RECONCILIATION OF NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS TO ADJUSTED EBITDA | ||||||||||||||||||||
(Unaudited, in thousands) | ||||||||||||||||||||
|
| Three months ended |
| Nine months ended |
|
| ||||||||||||||
|
|
| 2026 |
|
|
| 2025 |
|
|
| 2026 |
|
|
| 2025 |
|
| Outlook FY26 | ||
Net loss attributable to common stockholders |
| $ | (3,499 | ) |
| $ | (3,892 | ) |
| $ | (13,620 | ) |
| $ | (19,633 | ) |
| $ | (10,000 | ) |
Increase in net loss due to warrant modification |
|
| — |
|
|
| — |
|
|
| 1,921 |
|
|
| — |
|
|
| 1,921 |
|
Non-GAAP adjusted net loss |
|
| (3,499 | ) |
|
| (3,892 | ) |
|
| (11,699 | ) |
|
| (19,633 | ) |
|
| (8,079 | ) |
Depreciation and amortization |
|
| 754 |
|
|
| 1,181 |
|
|
| 2,266 |
|
|
| 3,142 |
|
|
| 3,000 |
|
Stock-based compensation |
|
| 2,472 |
|
|
| 1,763 |
|
|
| 7,071 |
|
|
| 5,491 |
|
|
| 9,500 |
|
Gain on sale of equipment, net |
|
| — |
|
|
| — |
|
|
| (278 | ) |
|
| — |
|
|
| — |
|
|
| — |
|
|
| 1,575 |
|
|
| 1,216 |
|
|
| 5,034 |
|
|
| — |
| |
Interest and foreign exchange |
|
| (755 | ) |
|
| (450 | ) |
|
| (1,716 | ) |
|
| (1,139 | ) |
|
| (1,700 | ) |
Adjusted EBITDA |
| $ | (1,028 | ) |
| $ | 177 |
|
| $ | (3,140 | ) |
| $ | (7,105 | ) |
| $ | 2,721 |
|
We define non-GAAP adjusted EBITDA as net loss attributable to common stockholders before interest, taxes, depreciation and amortization, stock-based compensation expense, the non-cash impact of the increase in fair value related to the warrant exchange and other items, which occur from time to time and which we do not believe are indicative of our core operating results.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261110308758/en/
Investors
949-574-3860
IR@amprius.com
Media
949-574-3860
Amprius@Gateway-grp.com
Source: